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Abstract
Background: In cancer prognosis research, diverse machine learning models have applied to the problems of
cancer susceptibility (risk assessment), cancer recurrence (redevelopment of cancer after resolution), and cancer
survivability, regarding an accuracy (or an AUC–the area under the ROC curve) as a primary measurement for the
performance evaluation of the models. However, in order to help medical specialists to establish a treatment plan
by using the predicted output of a model, it is more pragmatic to elucidate which variables (markers) have most
significantly influenced to the resulting outcome of cancer or which patients show similar patterns.
Methods: In this study, a coupling approach of two sub-modules–a predictor and a descriptor–is proposed. The
predictor module generates the predicted output for the cancer outcome. Semi-supervised learning co-training
algorithm is employed as a predictor. On the other hand, the descriptor module post-processes the results of the
predictor module, mainly focusing on which variables are more highly or less significantly ranked when describing
the results of the prediction, and how patients are segmented into several groups according to the trait of
common patterns among them. Decision trees are used as a descriptor.
Results: The proposed approach, ‘predictor-descriptor,’ was tested on the breast cancer survivability problem based
on the surveillance, epidemiology, and end results database for breast cancer (SEER). The results present the
performance comparison among the established machine leaning algorithms, the ranks of the prognosis elements
for breast cancer, and patient segmentation. In the performance comparison among the predictor candidates,
Semi-supervised learning co-training algorithm showed best performance, producing an average AUC of 0.81. Later,
the descriptor module found the top-tier prognosis markers which significantly affect to the classification results on
survived/dead patients: ‘lymph node involvement’, ‘stage’, ‘site-specific surgery’, ‘number of positive node
examined’, and ‘tumor size’, etc. Also, a typical example of patient-segmentation was provided: the patients
classified as dead were grouped into two segments depending on difference in prognostic profiles, ones with
serious results with respect to the pathologic exams and the others with the feebleness of age.
Background
Breast cancer is the second most lethal cancer in
women (Lung cancer is the leading cancer killer in
women), and represents 14.1% of all new cancer cases in
the U.S. in 2013 [1,2]. The good news is that women are
living longer with breast cancer. The 5-year survival rate
for women diagnosed with breast cancer is 89.2% [2].
Due to early detection, increased accuracy in cancer
prognosis, and better treatment options, breast cancer
mortality rates declined by about 34% since 1990 [3].
Particularly, advances in cancer prognosis help both
physicians and patients in establishing an adjuvant treat-
ment plan [4-6]. A prognosis is an estimate of the likely
course and outcome of a disease. The prognosis of a
patient diagnosed with cancer is often viewed as the
chance that the disease will be treated successfully and
that the patient will recover. Cancer prognosis includes
susceptibility (cancer risk assessment), recurrence (rede-
velopment of cancer after resolution), and survivability
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(survivability of a patient, life expectancy, progression,
tumor-drug sensitivity, etc.) [7]. In this paper, we scope
the last one, survivability: whether a patient is to be or
not to be a survivor after 1,825 days (5 years) from the
date of cancer diagnosis.
Diverse predictive models from machine learning or
data mining have employed to perform predictions on
survivability. In [6], the authors conducted a wide ran-
ging investigation of different machine learning meth-
ods, discussing issues related to the types of data
incorporated and the performance of these techniques
in breast cancer prognosis. This review provides detailed
explanations leading to first-rate research guidelines for
the application of machine learning methods during
cancer prognosis. The authors of [5] used two popular
data mining algorithms, artificial neural networks
(ANN) and decision trees (DT), together with a com-
mon statistical method, logistic regression, to develop
prediction models for breast cancer survivability. The
DT was shown to be the best predictor. An improve-
ment in the results of DT for the prognosis of breast
cancer survivability is described in [4]. The authors pro-
pose a hybrid prognostic scheme based on weighted
fuzzy decision trees. This hybrid scheme is an effective
alternative to crisp classifiers that are applied indepen-
dently. In [8], the authors conducted data preprocessing
with RELIEF attribute selection and used the Modest
AdaBoost algorithm to predict breast cancer survivabil-
ity. The study used the Srinagarind hospital database.
The results showed that Modest AdaBoost performed
better than Real and Gentle AdaBoost. They then pro-
posed a hybrid scheme to generate a high quality data
set to develop improved breast cancer survival models
[9]. In [10], support vector machines (SVM) based clas-
sification was carried out concerning both the prognosis
and diagnosis problems of breast cancer. From the com-
parison results with ANN and Bayesian method, they
demonstrates the superiority of SVM in terms of sensi-
tivity, specificity and accuracy.
In prediction of survival of breast cancer patients, the
performance of the established machine learning models
including ANN, SVM, semi-supervised learning (SSL),
Bayesian Methods, etc., has been often compared and the
winner model is renewed paper by paper [4-6,8-11].
While such studies have been devoted to enhancement of
the predictive power or accuracy of the predictive model,
interpretability of the predicted results has received less
attention. Most of them are like a black-box module only
producing the prediction results and accuracy as a mea-
sure of performance for comparison. In other words, it is
difficult to know what happened during prediction and
how we obtained the results: for instance, the questions
like ‘which factors(variables) are most significantly con-
tributed to survival/death classification?’ or ‘are there
subgroups of patients that show a similar pattern?’ are
usually veiled. In practice, however, the answers for those
questions benefits for medical practitioners and patients in
many ways. By knowing the significant factors, we can
make a proper choice of therapy, which may elevate the
likelihood of successful treatments. At the same time,
redundant or unimportant factors for breast cancer can be
ruled out from then on, which will lead to reduction in
time and cost during data collection and during treatment
as well. On the other hand, patient segmentation (tying
similar patients as a group) also used to help determine
whether adjuvant treatments should be given to a particu-
lar patient, i.e., a doctor can decide whether a patient who
has had surgery may benefit from a certain type of che-
motherapy. The segmentation results based on the trait of
common patterns of the patients can help predict how
aggressive a patient’s cancer may be and how well the can-
cer may respond to certain types of drugs. Among the
representatives in machine learning models, a DT is a
model equipped with reasonably good general ability and
interpretability [5,12-14]. However, it would occur that its
performance does not reach to those of the up-to-date
models, i.e., SVM, SSL, Bayesian Methods [15,16]. To
investigate the predicted results further, one may not want
to simply give up using the winner model.
To circumvent the dilemma, we suggest a coupling
approach of two sub-modules–a predictor and a descrip-
tor. The predictor module generates the predicted output
for cancer survivability, and any relevant predictive
model can be employed as a predictor such as SVM,
ANN, SSL and Bayesian method, etc. In the current
study, we use the SSL based Co-training algorithm which
showed outperformance than others in the previous
study [11]. The model generates pseudo-labels by co-
training multiple SSL member models, which assign
them to unlabeled data before treating them as if they
were labeled. As the labeled data increase, the predictive
performance of the ordinary SSL increases. The algo-
rithm realizes the tenet of ‘the more labeled data, the bet-
ter prediction’ which would be applied to most machine
learning algorithms. On the other hand, the descriptor
module post-processes the results of the predictor mod-
ule, and provides variable importance and patient seg-
mentation: which variables are more highly or less
significantly ranked when describing the results of the
prediction, and how patients are segmented into several
groups according to the trait of common patterns,
respectively. Decision trees (DT) are used as a descriptor.
The rest of this paper is organized as follows. Section
2 presents the proposed ‘predictor-descriptor’ approach.
In the predictor module, SSL Co-training is explained
following a brief introduction to SSL. In the descriptor
module, variable importance and patient segmentation
are described. Section 3 shows the experimental results
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of the proposed method on the surveillance, epidemiol-
ogy, and end results (SEER) cancer incidence database,
which is the most comprehensive source of information
on cancer incidence and survival in the USA [2]. Perfor-
mance comparison of SSL Co-training and the latest
machine learning models, and interpretations with clini-
cal implications on the results are provided. In Section 4,
we present our conclusions.
Proposed method: a coupling approach of a
predictor and a descriptor
The proposed model is designed through two phases of
modeling: a predictor and a descriptor. The predictor
module generates the predicted labels for patient samples
on whether the patient will be survived or not. SSL
Co-training is employed as a model for the predictor mod-
ule [11]. After then, the descriptor module post-processes
the prediction results by using decision trees [12-14]. It
profiles the reasons which variables are most determinant
in identifying survived/dead patients, which translates as
variable importance. The descriptor module also provides
segmented results. A set of patients with similar values in
variables is called a segment. By segregating the survived
patients into homogeneous segments, a medical expert
now can tailor a proper investigative and treatment plan
for each segment. Figure 1 presents the overall procedure
of the proposed method.
The predictor module: semi-supervised learning and SSL
co-training
In many real applications, there is a large supply of unla-
beled data, and we can collect them with only a little
effort in general. However, we may not be able to obtain
enough labeled data since it is often costly, difficult, or
time consuming to generate the labels for data [17,18].
Recently, many machine learning researchers have found
that unlabeled data, when used in conjunction with a
small amount of labeled data, can produce considerable
improvement in learning accuracy. And it is “para-
digmed” as semi-supervised learning or simply SSL. SSL
exploits the knowledge of the input structure from unla-
beled data and at the same time utilizes the label infor-
mation provided by labeled data.
SSL may be a good candidate to use a predictive model
for cancer survivability, particularly when the available
dataset for model learning has an abundance of unlabeled
patient cases but a lack of labeled ones. Like many other
machine learning algorithms, however, the availability of
more labeled data leads to better performance. This
motivated our previous work, SSL Co-training [11]. The
proposed model generates “pseudo-labels” and it
increases the performance of SSL. The model is based on
graph-based SSL [19,20].
In graph-based SSL, a weighted graph is constructed
where the nodes represent the labeled and unlabeled
data points while the edges reflect the similarity between
data points. Figure 2(a) depicts a graph with two labeled
and three unlabeled data points. Given n(= nl + nu) data
points from the sets of labeled L = {(xi, yi)nli=1} and unla-
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where i ~ j indicates that the two nodes are con-
nected, and the value of the similarity is represented by
a matrix W = {wij}. Then the label information can pro-
pagate from (labeled) node xi to node (unlabeled) node
xj when they are coupled by a path of high density (e.g.,
the value of wij is large), their outputs are likely to be
close, whereas their outputs need not be close if they
are separated by a low-density region (e.g., the value of
wij is small) [15,16,19,20].






]T = (f1, . . . , fl, fl+1, . . . , fn=l+u)T, which
can generate a threshold value to perform the label predic-
tions on (f1, . . . , fn) as a result of the learning. There are
two assumptions: a loss function ( fi should be close to the
given label of yi in labeled nodes) and label smoothness
(overall, fi should not be too different from fi for the neigh-
boring nodes). These assumptions are reflected in the value
Figure 1 Schematic description on the procedure of the proposed method. Schematic description on the procedure of the proposed
method.
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f − y)T (f − y) + μf TLf , (2)
where y =
[
y1, . . . , yl, 0, . . . , 0
]T and the matrix L,
which is known as the graph Laplacian matrix, is




The parameter μ trades off loss and smoothness. Thus,
the solution of this problem becomes
f = (I + μL)−1y. (3)
Based on the basic framework of graph-based SSL,
SSL Co-training obtains more labeled data by assigning
labels to unlabeled data, i.e., “pseudo-labels,” and uses
them for model learning as if they were labeled. The
model involves multiple member models where pseudo-
labels are determined based on agreements among the
members. Therefore, it is named as SSL Co-training
[11]. The toy example shown in Figure 1 is helpful for
understanding the model.
In the beginning Figure 2, the two data points x1 and x5
belong to the labeled set L = {(x1, +1), (x2,−1)} and the
labels are given as y1 = +1 and y5 = −1, respectively. x2, x3,
and x4 belong to the unlabeled datasetU = {x2, x2, x3}. For
simplicity, we assume that two member models, F1 and F2,
are provided (more concretely, two SSL classifiers) and
that they are independent. At the start of the algorithm,
each of the two classifiers is trained on L andU following
the objective function in (2) as an ordinary SSL. After
training (iteration 1) in Figure 3, the predicted labels for
the three data points are given by F1 and F2. For x2, the
two classifiers agree on labeling y12 = y
2
2 = +1, so its
pseudo-label becomes y2 = 1. Likewise, x4 obtains the
pseudo-label y4 = −1. However, the two members disagree
on the labeling of x3 : y13 = +1 but y
2
3 = −1. Therefore, it
remains unlabeled. In the next iteration (iteration 2) in
Figure 4, the labeled dataset is increased by the two
pseudo-labeled data points L = {(x1, +1), (x2, +1), (x3,−1), (x4,−1)},
and the unlabeled data set is decreased toU = {x3}. Similar
to the previous iteration, F1 and F2 provide x3 with the pre-
dicted labels y13 = +1 and y
2
3 = −1, respectively. However,
they still fail to agree on the labeling of x3. This leads to the
same result as the previous iteration, so the iteration stops.
SSL Co-training increases the performance of an ordinary
SSL thanks to the pseudo-labeled data points. Further
details on the method can be found in [11].
Figure 2 Original SSL Graph. In graph-based SSL, the labeled
nodes are represented by ‘+1(survived)’ and ‘-1(dead)’, whereas
unlabeled nodes are represented by ‘?’.
Figure 3 SSL Co-training: Predicted labels. The two figures 2 and
3 provide schematic description of SSL Co-training. At the start of
the algorithm, each of the member models (for simplicity, we
assume two classifiers) is trained on the original graph in Figure 2.
Figure 4 SSL Co-training: Pseudo labeled graph. After training,
both member models produce predicted labels for the unlabeled
nodes. The unlabeled nodes are pseudo-labeled when the member
models agree on labeling, or it remains unlabeled. The resulting
graph is shown in Figure 4.
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The descriptor module
In the descriptor module, we obtain information on the
importance of the variables used as input for the survi-
vability prediction, and the detailed segmentation for the
patient groups. The patient samples with predicted
labels by SSL Co-training are fed to decision trees (DT)
and re-classified. A DT is a traditional supervised learn-
ing model, and its general ability is known to be reason-
ably good [5,12-14]. This implies a DT itself can be
used as a predictive model for the breast cancer surviva-
bility. However, since there are more recent and sophis-
ticated models with a better performance such as SVM
and SSL (the comparison results are provided in the fol-
lowing experiment section), we opt to use a DT as a
post-processor for describing the results of those predic-
tive models. DT can provide interpretability on what
happened in the predictor module: for instance, ‘which
variables are most significantly contributed to survival/
death classification?’ and ‘are there subgroups of patients
that show a similar pattern?’, etc. The answers for the
questions are naturally obtained by reclassifying the
(variables, the predicted label) pairs of patient samples.
Note that neither a validation nor a test set is used
since the DT here is only employed for the purpose of
description on the output of the predictor module, not
for prediction. During the training, DT recursively splits
samples in a root node into two or more subgroups
until a final tree is constructed. While a tree is growing,
it identifies a splitting variable and corresponding
threshold value that maximizes the homogeneity of the
resulting two or more subgroups of samples.
The issue of variable importance is related to the splitting
criteria of DT. The most well-known criteria includes Gini
index (used in CART) [13], Entropy based information gain
(used in ID3, C4.5, C5) [12], and Chi-squared test (used in
CHAID) [14]. There are some differences among those cri-
teria, the commonly used measure of importance is based
on the surrogate splits s˜x computes the improvement in
homogeneity by the splitting of variable x,I(s˜x, t), at each
ynode t in the final tree, t ∈ T. Then, the measure of impor-
tance M(x) of variable × is defined as the sum across all
splits in the tree of the improvements that x has when it is





Since only the relative magnitudes of the M(x) are inter-
esting, the actual values of variable importance are the
normalized quantities. The most important variable then






Figure 5 exemplifies a final tree after re-classification.
The leaf (shaded) nodes are labeled as either survived or
dead. One can figure out which variables contributed sig-
nificantly for the splitting by tracing down the tree from
the root node to the leaf. Generally, a variable in a higher
level is regarded as more important than the one in a
lower level. But it should be noted that those variables
that, while not giving the best split of a node, may give
the second or third best are often hidden in the final tree.
For instance, if classification accuracies of two variables
x1 and x2 are similar, assuming x1 is slightly better than
x2, then the variable x2 may never occur in any split in
the final tree. In such a situation, we would require the
measures in Eq.(4) and Eq.(5), the variable importance
based on surrogate split, to detect the importance of x2.
On the other hand, the issue on patient segmentation is
related to finding a route from the root node to a leaf
node in the resulting tree. From the binary classification
results of the predictor module, we only know difference
between the two groups of the survived patients and of
the dead. In practice, however, we may want to know
further. Looking into the records of the patients who are
predicted to be dead (or survived), for instance, there may
be several different reasons or patterns which lead them to
death (or survival). The segmentation on patients depend-
ing on difference in patterns can be obtained from the
resulting tree. Figure 5 shows a toy case: the patients who
are predicted to be highly likely to be dead are now segre-
gated into two segments: (a) the ones with a very high in
‘Number of Primaries’ and (b) the others with a low in
‘Number of Primaries’ but a high in ‘Stage’ and a large in
Figure 5 Using a decision tree to obtain variable importance
and segmentation by reclassifying the results of the predictor
module. Using a decision tree to obtain variable importance and
segmentation by reclassifying the results of the predictor module.
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‘Tumor Size’. Depending on the trait of the segment, one
can tailor an appropriate medical plan and action.
Experiments
Data
In this study, Surveillance, Epidemiology, and End Results
data (SEER, 1973-2003) is used for the experiment. SEER
is an initiative of the National Cancer Institute and the
premier source for cancer statistics in the United States
and claims to have one of the most comprehensive collec-
tions of cancer statistics [2,7]. The data consists of 162,500
records with 16 input variables and one target class vari-
able. It includes incidence, mortality, prevalence, survival,
lifetime risk, and statistics by race/ethnicity. Particularly,
survivability of patients with breast cancer depends on two
different types of prognostic variables: 1) chronological
(indicators of how long the cancer has been present, e.g.
tumor size) and 2) biological (indicators of metastatic
aggressive behavior of a tumor, e.g. tumor grade) [24].
They determine, either or not a particular tumor might
respond to a specific therapy. The 16 input variables are
tumor size, number of nodes, number of primaries, age at
diagnosis, number of positive nodes, marital status, race,
behavior code, grade, extension of tumor, node involve-
ment, histological Type ICD, primary site, site-specific sur-
gery, radiation, and stage. The target variable ‘survivability’
is a binary categorical feature with values ‘-1’ (not survived
or dead) or +1 (survived). Table 1 summarizes the vari-
ables and the corresponding descriptions.
Results of the predictor module
In the predictor module, the generalization abilities of five
representative predictive models, i.e., DT, ANN, SVM, SSL,
and SSL-Co training, were compared. The area under the
receiver operating characteristic (ROC) curve (AUC) was
used as performance measures [25]: the AUC assess the
overall performance of a classification model, which is a
threshold-independent measure based on the ROC curve
that plots the tradeoffs between sensitivity and 1−specificity
for all possible values of threshold. The breast cancer survi-
val dataset contains 128,469 positive cases and 34,031
negative cases. To avoid the difficulties in learning of the
predictive models, caused by the large-sized and class-
imbalanced dataset, 40,000 data points were used for the
training set and 10,000 for the test set, which were drawn
randomly without replacement. The equipoise dataset of
Table 1 Prognostic elements of breast cancer survivability (SEER).




1 Race Ethnicity: White, Black, Chinese, etc. 16
2 Radiation None, Beam Radiation, Radioisotopes, Refused, Recommended, etc. 6
3 Primary Site Presence of tumor at particular location in body. Topographical
classification of cancer.
9
4 Histological Type Form and structure of tumor 30
5 Behavior Code Normal or aggressive tumor behavior is defined using codes. 2





Information on surgery during first course of therapy, whether cancer-
directed or not.
12
8 Stage Defined by size of cancer tumor and its spread 10
9 Clinical Extension
of tumor
Defines the spread of the tumor relative to the breast 16
10 Lymph Node
Involvement
None, (1-3) Minimal, (4-9) Significant, etc. 7
11 Marital Status Married, Single, Divorced, Widowed, Separated 4
Continuous
Variables
12 Age at Diagnosis Actual age of patient in years 63.64 ± 14.25




When lymph nodes are involved in cancer, they are known as positive. 27.29 ± 42.26
15 Number of Nodes
Examined
The total number of (positive/negative) lymph nodes that were




Number of primary tumors (1-6) 0.54 ± 1.29
Survivability Target binary variable defines class of survival of patient.
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50,000 data points was eventually divided into ten groups
and five-fold cross validation was applied to each.
The model parameters were searched over the follow-
ing ranges for the respective models. For DT, CART was
employed with default setting [13]. It is a non-parametric
model, and hence it did not necessarily require parameter
searching. For ANN, the number of ‘hidden nodes’ and
the ‘random seed’ for the initial weights were searched
over hidden-node = {3, 6, 9, 12, 15} and random-seed =
{1, 3, 5, 7, 10} [26]. For SVM, the values for the RBF
kernel width ‘Gamma’ and the loss penalty term ‘C’ were
selected by searching the ranges of C = {0.2, 0.4, 0.6, 0.8,
1} and Gamma = {0.0001, 0.001, 0.01, 0.1, 1} [27]. For the
SSL and SSL Co-training models, the values for the num-
ber of neighbors ‘k’ and the tradeoff parameter ‘Mu’
between the smoothness condition and loss condition in
(1) were searched over k = {3, 7, 15, 20, 30} and Mu =
{0.0001, 0.01, 1, 100, 1000}, respectively.
Table 2 shows a comparison of the results with DT,
ANN, SVM, SSL, and SSL Co-training in terms of the
AUC. For each of the five models, the best performance
was selected by searching over the respective model-
parameter space. SSL Co-training produced an average
AUC of 0.81, which was the best of the five models
although comparable performance was delivered by
SVM. On the other hand, DT showed an average AUC of
0.73, and just ranked the worst performed model ANN.
Either DT or ANN may be a good predictive model for
some other problems, but are less likely to be the one
than other three models in the current study. Figure 6
visualizes the AUC performance of the five models using
bar graphs.
Results of the descriptor module
For each of the 10 data sets, the test samples with pre-
dicted labels were input to the descriptor module
together with the training samples. The labels for the test
samples were obtained from SSL Co-training, which per-
formed best among the five competing predictive models.
Figure 7 shows ranking of the 16 input variables in terms
of Eq.(5), the relative magnitudes to the value of the most
important variable. It shows that ‘Lymph Node Involve-
ment’ is the most determinant variable in identifying sur-
vived/dead patients, therefore it has a value of 1. And in
order of variable importance, ‘Stage’, ‘Site-specific Surgery’,
‘Number of Positive Nodes Examined’ and ‘Tumor Size’
belong to the top-tier ranked up to 5th variables, and are
regarded as more important ones than the rest.
The five variables are all related to the findings from a
pathologic exam. It is known as the best way to assess
lymph node status and can give a first estimate of breast
cancer stage and the size of tumor. Usually, a surgeon
removes some lymph nodes in the armpit with a technique
called sentinel node biopsy. Then, a pathologist studies
these nodes under a microscope. As part of the initial
work-up or first course of therapy, a surgical procedure
that removes and/or destroys tissue of the specific-site
performed. Prognosis is poorer when cancer has spread to
the lymph nodes (lymph node-positive). The more lymph
nodes that contain cancer, the poorer the prognosis tends
to be. Non-invasive and early stage invasive breast cancers
have a better prognosis than later stage cancers. And, the
poorest prognosis is for metastatic breast cancer, where
the cancer has spread beyond the lymph nodes to other
parts of the body. Enlarged nodes can be a sign of cancer
spread [28].
To discern that how those variables influence to clas-
sification, the two patient groups of the survived and
the dead were profiled, respectively. Figure 8 shows a
radial diagram of the average values of 16 variables for
the two patient groups. Each axis of the diagram repre-
sents a scaled value relative to its range. The grey line
in the center stands for the overall average of the vari-
able, whereas the blue/red line stands for the group
average of the survived/dead.
Compared the averages of the two groups, significant
differences can be found by ‘Lymph Node Involvement’,
‘Number of Positive Nodes Examined’, ‘Stage’, ‘Behavior
Code’, ‘Site-Specific Surgery’, ‘Tumor Size’, ‘Age at Diag-
nosis’, whereas ‘Marital Status’ and ‘Race’ do not provide
significant information on discriminating the two
groups. Relatively, a general pattern of the survived
patients is less involvement of lymph nodes, an earlier
stage, a smaller sized tumor, non-invasive in cancer
behavior, less (site-specific) surgeries, younger in terms
of age at diagnosis. On the other hand, the dead patients
show a pattern of larger spread of cancer over lymph
nodes, a larger tumor size, more aggressive and invasive
cancer behavior, more surgeries and radiation therapies,
and an older age at diagnosis.
Table 2 Performance (AUC) comparison of the five predictive models
Data Set 1 2 3 4 5 6 7 8 9 10 Avg.
DT 0.74 0.50 0.50 0.78 0.80 0.82 0.79 0.77 0.78 0.80 0.73
ANN 0.68 0.72 0.68 0.72 0.66 0.68 0.67 0.73 0.71 0.73 0.70
SVM 0.79 0.79 0.80 0.79 0.82 0.78 0.79 0.82 0.81 0.81 0.80
SSL 0.77 0.79 0.78 0.76 0.78 0.77 0.77 0.8 0.78 0.8 0.78
SSL Co-training 0.84 0.82 0.80 0.81 0.82 0.84 0.83 0.82 0.78 0.81 0.81
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The results of the predictor module were further
examined by segmenting the survived/dead patients into
several subgroups using DT. Figure 9 shows the first
three levels of the resulting tree. (The complete tree has
six levels with 15 leaf nodes.) The tree splits the root
node of the 5,000 patients into several children nodes
by successively choosing the most significant variables
in classifying the patients into the survived/dead. A vari-
able in a higher level of the tree is more important than
the one in a lower level. Similar results were obtained as
in variable importance: ‘Lymph Node Involvement’,
‘Number of Positive Nodes Examined’, ‘Age at Diagno-
sis’, ‘Stage’, and ‘Tumor Size’ were used as early splitters
of the tree, and in a full tree, ‘Grade’, ‘Site-Specific Sur-
gery’, ‘Number of Node Examined’, and ‘Primary Site’,
etc. were additionally included. As the tree grows, the
purity at the leaf nodes measured by the proportion of
patient assigned to the dominant class (either the sur-
vived or the dead) increases. In a node, the proportion
of the survived/dead are represented as a histogram, the
white bar is for the survived and the black one is for the
dead. A leaf node in the resulting tree is called a seg-
ment of the patients who are similar in their prognosis
factors. The segment profiling for a leaf node is deter-
mined by the variables (with the corresponding values)
that contributed significantly for the node-split by tra-
cing back the tree from the leaf node to the root. In the
tree, there are many leaf nodes and each of them has
different profiling, and therefore the patients who are
classified into a same class (either survived or dead) in
the predictor module are further segregated into several
segments in the description module depending on
which leaf nodes they belong to.
In Figure 9, two typical cases of patient segments,
(a) and (b), are marked with the red-outlined boxes.
Both belong to the class of the dead, but show differ-
ent reasons. The following two radial diagrams in
Figure 8 illustrate the difference.
Figure 6 Performance (AUC) comparison over 10 data sets. Performance (AUC) comparison over 10 data sets: DT, ANN, SVM, SSL, and SSL
Co-training.
Figure 7 Variable Importance. Variable importance: the 16 input variables are ranked by the order of variable importance Eq.(5).
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Figure 8 Variable Profiling. Variable profiling: average values of the 16 variables for (a) survived patients and (b) dead patients.
Figure 9 Patient Segmentation. Patient Segmentation: The first three levels of the resulting decision tree. In a node, the proportion of the
survived and the dead are represented as the white bar and the black bar, respectively.
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Compared with the averages of the dead patients in
Figure 8, the patient segment in Figure 10 shows a dif-
ferent pattern: low in ‘Lymph Node Involvement’, small
in ‘Tumor Size’, early in ‘Stage’, low in ‘Site-Specific
Surgery’, high in ‘Radiation’, but a very high peak in ‘Age
at Diagnosis’. One may make a mere conjecture that
those patients had not been so serious from the view-
point of the pathologic exam. Then, the main factor that
had driven them to death might have been the feebleness
of age (they are over age of 84). On the contrary, the
patient segment in Figure 11 shows a serious pattern
with respect to the pathologic results: a high peak in
‘Lymph Node Involvement’, large in ‘Number of Positive
Nodes Examined’, late in ‘Stage’, aggressive and invasive
in ‘Behavior Code’ of cancer, a larger number in
‘Site-Specific Surgery’.
Figure 10 and 11 only present a tip of the possibilities
of patient segmentation. With a more abundance of can-
cer prognosis factors, the presence of detailed segmenta-
tion can help predict the chances for long-term survival
of the patients and also guide proper treatments that fit
for each of the segments.
Figure 10 Patient Segmentation: Feebleness of age. Patient Segmentation: Two radial diagrams in Figure 10 and 11 illustrate difference of
patient segments in terms of patterns of prognosis factors.
Figure 11 Patient Segmentation: A serious pattern with respect to the pathologic results. Patient Segmentation: Two radial diagrams in
Figure 10 and 11 illustrate difference of patient segments in terms of patterns of prognosis factors.
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Conclusion
In this study, we proposed a model that predicts the
survivability of the breast cancer patients and provides
the interpretations on the results in terms of cancer
prognosis factors. The model is composed of two mod-
ules, a predictor and a descriptor. The predictor module
of the model classifies patients into two classes of the
survived and the dead, and then the descriptor module
calculates the importance of prognosis factors, and
groups the predicted patients with similar prognostic
profiles. There are three noteworthy features of the pro-
posed method. First, since the aim of the predictor
module is to obtain the best prediction, it was designed
to be flexible so that any winner model can be employed
among the up-to-date machine learning algorithms. In
this study, we used SSL Co-training which had been
well validated in the authors’ previous research [11].
Second, although the predictor module offers the best
prediction, it seldom provide explicit explicability of
which variable is the most significant during prediction.
To unveil the implicit mechanism of the prediction pro-
cedure, variable importance calculation was embedded
in the descriptor module. Knowing the significant vari-
ables will lead to better insights in cancer prognosis,
and less time and cost by excluding redundant ones
during data collection. In addition, the segmentation
based on the decision trees was also integrated into the
descriptor module. This can assist medical experts for
the further investigation on prognosis factors and for
the tailored treatment design according to unique fea-
tures of the patient segments.
The present study triggers possible future works. First,
the coupling approach of a predictor and a descriptor is
yet general and its full application for different cancer
types will still require a continued refinement, as well as
broadening the number of prognosis factors whose can-
cer-specific ones are then selectively included. Second,
from a pragmatic perspective, the importance ranking
for cancer prognosis factors and the patient segments
require practical checking by medical specialists. To
incorporate this procedure systematically, an interactive
mode which reflects intervention from users should be
studied further.
Through this work, we would like to remark the follow-
ings reflecting reviewer’s comment. In most studies which
have applied a prediction algorithm to the medical domain
problems, it is more or less missing that why the algorithm
obtains the performance or how clinicians can put the
obtained results into practice. Although the novelty of
applied algorithms may only matter big to informaticians,
but to clinicians, which algorithm is more novel or per-
forms better than the other may not be the only concern.
Rather, they need more kindness so that they better
understand what happened in the prediction algorithm
and its usability to the domain afterwards. This blind spot
in informaticians’ approaches to medical domain drives
the motivation of this work. To take a broad view of this
work, its value lies in that it is not only concerns the per-
formance in prediction but also aware of the importance
of description that raises clinicians’ comprehension and
practical usability of the method to the domain.
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